Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

Abstract

Interferon (IFN) was the first cytokine discovered 50 years ago, with a wide range of biological properties, including immunomodulatory, proapoptotic and antiangiogenic activities, that rapidly raised interest in its therapeutic use in malignancies. IFN-receptor characterization was also pivotal in the discovery of the JAK/STAT signaling pathway. Among the large IFN family, mainly one of the type I IFN, IFN-α2, is used in therapy. Many clinical trials have shown remarkable efficacy of IFN-α in bcr-abl-negative myeloproliferative neoplasms (MPNs), especially polycythemia vera (PV), and essential thrombocythemia (ET). IFN-α induces about 80% of hematological responses in those diseases and is able to reduce splenomegaly, as well as relieve pruritus and other constitutional symptoms. Yet its use was limited by toxicity, leading to early treatment discontinuation in about 20% of the patients. However, its lack of leukemogenic potential and its possible use during pregnancy have already made IFN-α the drug of choice for younger MPN patients. In addition, several studies have shown a probably selective effect of IFN-α on PV and ET clones, as shown by cytogenetic remissions, reversions to polyclonal hematopoiesis, and more recently by induction of JAK2V617F complete molecular remissions in PV which may widen the indications of IFN-α in JAK2-mutated MPN.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Isaacs A, Lindenmann J . Virus interference.I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258–267.

    CAS  PubMed  Google Scholar 

  2. Pestka S, Krause CD, Walter MR . Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8–32.

    CAS  PubMed  Google Scholar 

  3. Krause CD, Pestka S . Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005; 106: 299–346.

    CAS  PubMed  Google Scholar 

  4. Cantell K, Hirvonen S, Kauppinen HL, Myllyla G . Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981; 78 (Part A): 29–38.

    CAS  PubMed  Google Scholar 

  5. Derynck R, Content J, DeClercq E, Volckaert G, Tavernier J, Devos R et al. Isolation and structure of a human fibroblast interferon gene. Nature 1980; 285: 542–547.

    CAS  PubMed  Google Scholar 

  6. Maeda S, McCandliss R, Gross M, Sloma A, Familletti PC, Tabor JM et al. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc Natl Acad Sci USA 1980; 77: 7010–7013.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980; 284: 316–320.

    CAS  PubMed  Google Scholar 

  8. Pestka S . The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282: 20047–20051.

    CAS  PubMed  Google Scholar 

  9. de Weerd NA, Samarajiwa SA, Hertzog PJ . Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007; 282: 20053–20057.

    CAS  PubMed  Google Scholar 

  10. Krause CD, Mei E, Xie J, Jia Y, Bopp MA, Hochstrasser RM et al. Seeing the light: preassembly and ligand-induced changes of the interferon gamma receptor complex in cells. Mol Cell Proteomics 2002; 1: 805–815.

    CAS  PubMed  Google Scholar 

  11. Platanias LC . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375–386.

    CAS  PubMed  Google Scholar 

  12. Tough DF, Sun S, Zhang X, Sprent J . Stimulation of naive and memory T cells by cytokines. Immunol Rev 1999; 170: 39–47.

    CAS  PubMed  Google Scholar 

  13. Ortaldo JR, Mason A, Rehberg E, Moschera J, Kelder B, Pestka S et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983; 258: 15011–15015.

    CAS  PubMed  Google Scholar 

  14. Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987; 235: 895–898.

    CAS  PubMed  Google Scholar 

  15. Carlo-Stella C, Cazzola M, Gasner A, Barosi G, Dezza L, Meloni F et al. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987; 70: 1014–1019.

    CAS  PubMed  Google Scholar 

  16. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I . The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 1994; 87: 621–623.

    CAS  PubMed  Google Scholar 

  17. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC . Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 1990; 75: 188–194.

    CAS  PubMed  Google Scholar 

  18. Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H . Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161–162.

    CAS  PubMed  Google Scholar 

  19. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT . Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101: 3294–3301.

    CAS  PubMed  Google Scholar 

  20. Massaro P, Foa P, Pomati M, LaTargia ML, Iurlo A, Clerici C et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol 1997; 56: 126–128.

    CAS  PubMed  Google Scholar 

  21. Messora C, Bensi L, Vecchi A, Longo R, Giacobbi F, Temperani P et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol 1994; 86: 402–404.

    CAS  PubMed  Google Scholar 

  22. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera. Blood 2008; PMID:18650451 [e-pub ahead of print].

  23. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108: 2037–2040.

    Article  CAS  PubMed  Google Scholar 

  24. Chott A, Gisslinger H, Thiele J, Fritz E, Linkesch W, Radaszkiewicz T et al. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1990; 74: 10–16.

    CAS  PubMed  Google Scholar 

  25. Wang Q, Miyakawa Y, Fox N, Kaushansky K . Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093–2099.

    CAS  PubMed  Google Scholar 

  26. Silver RT . Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988; 2: 403.

    CAS  PubMed  Google Scholar 

  27. Bellucci S, Harousseau JL, Brice P, Tobelem G . Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988; 2: 960–961.

    CAS  PubMed  Google Scholar 

  28. Giles FJ, Singer CR, Gray AG, Yong KL, Brozovic M, Davies SC et al. Alpha-interferon therapy for essential thrombocythaemia. Lancet 1988; 2: 70–72.

    CAS  PubMed  Google Scholar 

  29. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Calogero RD . Recombinant interferon alpha in the treatment of polycythemia vera. Blood 1991; 77: 2790–2791.

    CAS  PubMed  Google Scholar 

  30. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferrara F . Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am J Hematol 1993; 44: 155–157.

    CAS  PubMed  Google Scholar 

  31. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S . Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol 1993; 43: 316–318.

    CAS  PubMed  Google Scholar 

  32. Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A . Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 1991; 76: 75–77.

    CAS  PubMed  Google Scholar 

  33. Papineschi F, Bucalossi A, Capochiani E, Benedetti E, Bramanti E, Dastoli G et al. Recombinant alpha 2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur J Haematol 1994; 53: 213–217.

    CAS  PubMed  Google Scholar 

  34. Sacchi S, Leoni P, Liberati M, Riccardi A, Tabilio A, Tartoni P et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol 1994; 68: 247–250.

    CAS  PubMed  Google Scholar 

  35. Muller EW, de Wolf JT, Egger R, Wijermans PW, Huijgens PC, Halie MR et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 1995; 89: 313–318.

    CAS  PubMed  Google Scholar 

  36. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT . Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J Haematol 1996; 92: 55–59.

    CAS  PubMed  Google Scholar 

  37. Foa P, Massaro P, Caldiera S, LaTargia ML, Iurlo A, Clerici C et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur J Haematol 1998; 60: 273–277.

    CAS  PubMed  Google Scholar 

  38. Gilbert HS . Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 1998; 83: 1205–1213.

    CAS  PubMed  Google Scholar 

  39. Stasi R, Venditti A, Del Poeta G, Conforti M, Brunetti M, Bussa S et al. Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera. Am J Med Sci 1998; 315: 237–241.

    CAS  PubMed  Google Scholar 

  40. Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H . The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol 1999; 62: 27–31.

    CAS  PubMed  Google Scholar 

  41. Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 98: 100–109.

    CAS  PubMed  Google Scholar 

  42. Silver RT . Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006; 107: 451–458.

    CAS  PubMed  Google Scholar 

  43. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006; 106: 2397–2405.

    CAS  PubMed  Google Scholar 

  44. Gugliotta L, Bagnara GP, Catani L, Gaggioli L, Guarini A, Zauli G et al. In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989; 71: 177–181.

    CAS  PubMed  Google Scholar 

  45. Lazzarino M, Vitale A, Morra E, Gagliardi A, Bernasconi P, Torromeo C et al. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 1989; 72: 173–177.

    CAS  PubMed  Google Scholar 

  46. Giralt M, Rubio D, Cortes MT, San Miguel J, Steegmann JL, Serena J et al. alpha Interferon in the management of essential thrombocythaemia. Eur J Cancer 1991; 27 (Suppl 4): S72–S74.

    PubMed  Google Scholar 

  47. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H . Interferon in essential thrombocythaemia. Br J Haematol 1991; 79 (Suppl 1): 42–47.

    PubMed  Google Scholar 

  48. Sacchi S, Tabilio A, Leoni P, Riccardi A, Vecchi A, Messora C et al. Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann Hematol 1991; 63: 206–209.

    CAS  PubMed  Google Scholar 

  49. Seewann HL, Zikulnig R, Gallhofer G, Schmid C . Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. Eur J Cancer 1991; 27 (Suppl 4): S58–S62; discussion S62–53.

    PubMed  Google Scholar 

  50. Kasparu H, Bernhart M, Krieger O, Lutz D . Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur J Haematol 1992; 48: 33–36.

    CAS  PubMed  Google Scholar 

  51. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R . Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol 1994; 91: 126–129.

    CAS  PubMed  Google Scholar 

  52. Berte R, Vallisa D, Ferrari B, Civardi G, Sbolli G, Cavanna L . Low-dose interferon alpha treatment in essential thrombocythemia. Eur J Haematol 1996; 56: 104–105.

    CAS  PubMed  Google Scholar 

  53. Sacchi S, Gugliotta L, Papineschi F, Liberati AM, Rupoli S, Delfini C et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 1998; 12: 289–294.

    CAS  PubMed  Google Scholar 

  54. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003; 51: 81–86.

    CAS  PubMed  Google Scholar 

  55. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 2005; 103: 2551–2557.

    CAS  PubMed  Google Scholar 

  56. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 2005; 90: 1333–1338.

    CAS  PubMed  Google Scholar 

  57. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007; 110: 2012–2018.

    CAS  PubMed  Google Scholar 

  58. Tefferi A, Elliot MA, Yoon SY, Li CY, Mesa RA, Call TG et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 1896.

    CAS  PubMed  Google Scholar 

  59. Heis-Vahidi-Fard N, Forberg E, Eichinger S, Chott A, Lechner K, Gisslinger H . Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study. Ann Hematol 2001; 80: 79–82.

    CAS  PubMed  Google Scholar 

  60. Kozlowski A, Charles SA, Harris JM . Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001; 15: 419–429.

    CAS  PubMed  Google Scholar 

  61. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556–567.

    CAS  PubMed  Google Scholar 

  62. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18: 309–315.

    CAS  PubMed  Google Scholar 

  63. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106: 2849–2853.

    CAS  PubMed  Google Scholar 

  64. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.

    CAS  PubMed  Google Scholar 

  65. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M . Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401–2407.

    CAS  PubMed  Google Scholar 

  66. Steegmann JL, Requena MJ, Martin-Regueira P, De La Camara R, Casado F, Salvanes FR et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha. Am J Hematol 2003; 72: 170–176.

    CAS  PubMed  Google Scholar 

  67. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70–74.

    CAS  PubMed  Google Scholar 

  68. Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S . Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. Haematologica 1996; 81: 533–535.

    CAS  PubMed  Google Scholar 

  69. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. ‘Leukemia and Hematosarcoma’ Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981; 44: 75–80.

  70. Berk PD, Wasserman L, Fruchtman S, Goldberg JT . Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera sub-group. In: Wasserman L, Berk PD (eds). Treatment of Polycythaemia Vera, a Summary of Clinical Trends Conducted by the Polycythaemia Vera Study Group. W.B. Saunders: Philadelphia, PA, 1995, pp 166–194.

    Google Scholar 

  71. Najean Y, Rain JD . Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370–3377.

    CAS  PubMed  Google Scholar 

  72. Najean Y, Rain JD . Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997; 89: 2319–2327.

    CAS  PubMed  Google Scholar 

  73. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664–2670.

    CAS  PubMed  Google Scholar 

  74. Murphy S, Peterson P, Iland H, Laszlo J . Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.

    CAS  PubMed  Google Scholar 

  75. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616–622.

    CAS  PubMed  Google Scholar 

  76. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A . Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138: 354–358.

    PubMed  Google Scholar 

  77. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270–276.

    CAS  PubMed  Google Scholar 

  78. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755–761.

    PubMed  Google Scholar 

  79. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148: 939–955.

    PubMed  PubMed Central  Google Scholar 

  80. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P . Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32 (4 Part 2): 417–421.

    CAS  PubMed  Google Scholar 

  81. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–232.

    CAS  PubMed  Google Scholar 

  82. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174–195.

    PubMed  Google Scholar 

  83. Pardanani A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23–30.

    CAS  PubMed  Google Scholar 

  84. Lengfelder E, Berger U, Hehlmann R . Interferon alpha in the treatment of polycythemia vera. Ann Hematol 2000; 79: 103–109.

    CAS  PubMed  Google Scholar 

  85. Lengfelder E, Griesshammer M, Hehlmann R . Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996; 22 (Suppl 1): 135–142.

    PubMed  Google Scholar 

  86. Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006; 20: 1181–1183.

    CAS  PubMed  Google Scholar 

  87. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377–1380.

    CAS  PubMed  Google Scholar 

  88. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32–38.

    CAS  PubMed  Google Scholar 

  89. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107: 2206–2211.

    CAS  PubMed  Google Scholar 

  90. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676–3682.

    CAS  PubMed  Google Scholar 

  91. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952–1959.

    CAS  PubMed  Google Scholar 

  92. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T . Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523–530.

    CAS  PubMed  Google Scholar 

  93. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702–711.

    CAS  PubMed  Google Scholar 

  94. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Dos Santos F et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008; PMID:18728027 [e-pub ahead of print].

  95. Ricksten A, Palmqvist L, Johansson P, Andreasson B . Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008; 93: 1260–1261.

    CAS  PubMed  Google Scholar 

  96. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.

    CAS  PubMed  Google Scholar 

  97. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A . The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83: 363–365.

    CAS  PubMed  Google Scholar 

  98. Griesshammer M, Struve S, Harrison CM . Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 2006; 32 (4 Part 2): 422–429.

    PubMed  Google Scholar 

  99. Harrison C . Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293–306.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J-J Kiladjian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiladjian, JJ., Chomienne, C. & Fenaux, P. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22, 1990–1998 (2008). https://doi.org/10.1038/leu.2008.280

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.280

Keywords

This article is cited by

Search

Quick links